Key facts
- Matrix Capital Management Company, LP filed SCHEDULE 13G/A for Maze Therapeutics, Inc. Common Stock, par value $0.001 per share (MAZE).
- Disclosed ownership: 3.5%.
- Date of event: 30 Sep 2025.
Matrix Capital Management Company, LP - 30 Sep 2025 SCHEDULE 13G/A Report for Maze Therapeutics, Inc. Common Stock, par value $0.001 per share (MAZE)
- Filing Manager
- Matrix Capital Management Company, LP
- Reporting Manager
- Matrix Capital Management Company, LP
- Symbol
- MAZE
- Shares outstanding
- 47,248,114 shares
- Disclosed Ownership
- 1,653,684 shares
- Ownership
- 3.5%
- Form type
- SCHEDULE 13G/A
- Filing time
- 13 Nov 2025, 16:10:25 UTC
- Date of event
- 30 Sep 2025
- Previous filing
- 14 May 2025
- SEC
- View on sec.gov
Key filing fact
Matrix Capital Management Company, LP disclosed 3.5% ownership in Maze Therapeutics, Inc. Common Stock, par value $0.001 per share (MAZE) on 30 Sep 2025.
Change
- Previous schedule filing date: 14 May 2025.
- Current filing was accepted on 13 Nov 2025, 16:10.
Research use
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Reporting managers (2)
Names, ownership, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Matrix Capital Management Company, LP | 3.5% | 1,653,684 | 0 | 1,653,684 | /s/ David E. Goel | David E. Goel, Managing General Partner | |
| DAVID E. GOEL | 3.5% | 1,653,684 | 0 | 1,653,684 | /s/ David E. Goel | David E. Goel, individually |
CIK / CUSIP context first